Indonesia in Bold Move to Obtain Cheap Drugs for HIV
Abstract
On September 3, Indonesia’s government quietly issued an order to override patents on seven important medicines used to treat individuals with HIV and hepatitis B, which will allow more inexpensive versions to be manufactured by local pharmaceutical companies. There appeared to be no protest from the pharmaceutical giants, who in the past would have defended their patents very aggressively. The drug patents belong to Merck, GSK, Bristol-Myers Squibb, Abbott, and Gilead. The drugs include Glaxo ’s Abacavir, Abbott’s Kaletra, and Gilead’s tenofovir (Viread) which treats hepatitis B as well as providing the primary prevention treatment for those whose partners are HIV positive.
Indonesia’s HIV incidence rate is not particularly high—UNICEF estimates that nearly 310,000 individuals are infected—but it does have the fourth highest population in the world and the virus continues to spread. Only approximately 23,000 of the 70,000 individuals infected with HIV who need drug treatment are getting it.
Source
http://www.guardian.co.uk
Date of Publication
10/11/2012
Author
Sarah Boseley
Article Type
General media
Article Category
International News
Disclaimer: NPIN provides this information as a public service only. The views and information provided about the materials, funding opportunities, and organizations do not necessarily state or reflect those of the U.S. Department of Health and Human Services, CDC, or NPIN.
